Yeaseul Yoon

Yeaseul Yoon

Auto-generated profile, based on publicly available information

Yeaseul Yoon

Program in Public Health, Korea University, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
JSJiyoon Shin
Jiyoon Shin
SKSujin Kim
Sujin Kim
JLJooyoung Lee
Jooyoung Lee
HGHyerin Gu
Hyerin Gu
JAJihye Ahn
Jihye Ahn
YLYu Jin Lee
Yu Jin Lee
Background: Cognitive behavioral therapy for insomnia (CBTi) is the first-line therapy for chronic insomnia. Mobile app–based CBTi (MCBTi) can enhance the accessibility of CBTi treatment; however, few studies have evaluated the effectiveness of MCBTi using a multicenter, randomized controlled trial design. Objective: We aimed to assess the efficacy of Somzz, an MCBTi that provides real-time and tailored feedback to users, through comparison with an active comparator app. Methods: In our multicenter, single-blind randomized controlled trial study, participants were recruited from 3 university hospitals and randomized into a Somzz group and a sleep hygiene education (SHE) group at a 1:1 ratio. The intervention included 6 sessions for 6 weeks, with follow-up visits over a 4-month period. The Somzz group received audiovisual sleep education, guidance on relaxation therapy, and real-time feedback on sleep behavior. The primary outcome was the Insomnia Severity Index score, and secondary outcomes included sleep diary measures and mental health self-reports. We analyzed the outcomes based on the intention-to-treat principle. Results: A total of 98 participants were randomized into the Somzz (n=49, 50%) and SHE (n=49, 50%) groups. Insomnia Severity Index scores for the Somzz group were significantly lower at the postintervention time point (9.0 vs 12.8; t95=3.85; F2,95=22.76; ηp2=0.13; P<.001) and at the 3-month follow-up visit (11.3 vs 14.7; t68=2.61; F2,68=5.85; ηp2=0.03; P=.01) compared to those of the SHE group. The Somzz group maintained their treatment effect at the postintervention time point and follow-ups, with a moderate to large effect size (Cohen d=–0.62 to –1.35; P<.01 in all cases). Furthermore, the Somzz group showed better sleep efficiency (t95=–3.32; F2,91=69.87; ηp2=0.41; P=.001), wake after sleep onset (t95=2.55; F2,91=51.81; ηp2=0.36; P=.01), satisfaction (t95=–2.05; F2,91=26.63; ηp2=0.20; P=.04) related to sleep, and mental health outcomes, including depression (t95=2.11; F2,94=29.64; ηp2=0.21; P=.04) and quality of life (t95=–3.13; F2,94=54.20; ηp2=0.33; P=.002), compared to the SHE group after the intervention. The attrition rate in the Somzz group was 12% (6/49). Conclusions: Somzz outperformed SHE in improving insomnia, mental health, and quality of life. The MCBTi can be a highly accessible, time-efficient, and effective treatment option for chronic insomnia, with high compliance. Trial Registration: Clinical Research Information Service (CRiS) KCT0007292; https://cris.nih.go.kr/cris/search/detailSearch.do?seq=22214&search_page=L

25 August 2024 in Psychiatry Investigation
Verified
Journal Article
Open access
PDF file
JYJi Won Yeom
Ji Won Yeom
YYYeaseul Yoon
Yeaseul Yoon
JSJu Yeon Seo
Ju Yeon Seo
CCChul-Hyun Cho
Chul-Hyun Cho
TLTaek Lee
Taek Lee
HLHeon-Jeong Lee
Heon-Jeong Lee
The circadian rhythm for mood (CRM) is a digital therapeutic, which aims to prevent mood episode and improve clinical course in patients with major mood disorders. Developed on the circadian rhythm hypothesis of mood disorder, CRM predicts the impending risk of mood episode with its built-in algorithm, utilizing wearable devices data and daily self-reports, and provides personalized feedback. In a pilot study of the CRM, the users experienced less frequent and shorter duration of mood episodes than the non-users. To investigate the efficacy of the upgraded CRM, a double-blind, randomized, sham-controlled, parallel-group trial is designed. Patients aged between 19 and 70, diagnosed with bipolar I disorder, bipolar II disorder, or major depressive disorder, in a euthymic state for more than two months, can participate. During this 12-month trial, participants are assessed for episode recurrence every three months, and the efficacy of the CRM as a potential digital therapeutic is evaluated. Trial registration: ClinicalTrials.gov Identifier: NCT05400785.

6 July 2023 in JMIR Preprints
Verified
Preprint
Open access
JSJiyoon Shin
Jiyoon Shin
SKSujin Kim
Sujin Kim
JLJooyoung Lee
Jooyoung Lee
HGHyerin Gu
Hyerin Gu
JAJihye Ahn
Jihye Ahn
YLYu Jin Lee
Yu Jin Lee
BACKGROUND Cognitive behavioral therapy for insomnia (CBTi) is the first-line therapy for chronic insomnia. Mobile app–based CBTi (MCBTi) can enhance the accessibility of CBTi treatment; however, few studies have evaluated the effectiveness of MCBTi using a multicenter, randomized controlled trial design. OBJECTIVE We aimed to assess the efficacy of Somzz, an MCBTi that provides real-time and tailored feedback to users, through comparison with an active comparator app. METHODS In our multicenter, single-blind randomized controlled trial study, participants were recruited from 3 university hospitals and randomized into a Somzz group and a sleep hygiene education (SHE) group at a 1:1 ratio. The intervention included 6 sessions for 6 weeks, with follow-up visits over a 4-month period. The Somzz group received audiovisual sleep education, guidance on relaxation therapy, and real-time feedback on sleep behavior. The primary outcome was the Insomnia Severity Index score, and secondary outcomes included sleep diary measures and mental health self-reports. We analyzed the outcomes based on the intention-to-treat principle. RESULTS A total of 98 participants were randomized into the Somzz (n=49, 50%) and SHE (n=49, 50%) groups. Insomnia Severity Index scores for the Somzz group were significantly lower at the postintervention time point (9.0 vs 12.8; t95=3.85; F2,95=22.76; ηp2=0.13; P<.001) and at the 3-month follow-up visit (11.3 vs 14.7; t68=2.61; F2,68=5.85; ηp2=0.03; P=.01) compared to those of the SHE group. The Somzz group maintained their treatment effect at the postintervention time point and follow-ups, with a moderate to large effect size (Cohen d=–0.62 to –1.35; P<.01 in all cases). Furthermore, the Somzz group showed better sleep efficiency (t95=–3.32; F2,91=69.87; ηp2=0.41; P=.001), wake after sleep onset (t95=2.55; F2,91=51.81; ηp2=0.36; P=.01), satisfaction (t95=–2.05; F2,91=26.63; ηp2=0.20; P=.04) related to sleep, and mental health outcomes, including depression (t95=2.11; F2,94=29.64; ηp2=0.21; P=.04) and quality of life (t95=–3.13; F2,94=54.20; ηp2=0.33; P=.002), compared to the SHE group after the intervention. The attrition rate in the Somzz group was 12% (6/49). CONCLUSIONS Somzz outperformed SHE in improving insomnia, mental health, and quality of life. The MCBTi can be a highly accessible, time-efficient, and effective treatment option for chronic insomnia, with high compliance. CLINICALTRIAL Clinical Research Information Service (CRiS) KCT0007292; https://cris.nih.go.kr/cris/search/detailSearch.do?seq=22214&search_page=L

30 June 2022 in Chronobiology in Medicine
Verified
Journal Article
Open access
PDF file
SKSojeong Kim
Sojeong Kim
YYYeaseul Yoon
Yeaseul Yoon
HLHeon-Jeong Lee
Heon-Jeong Lee
Objective: Chronotype and impulsivity are important features to be examined in mood disorder patients; these characteristics precede mood disorder onset and persist between mood episodes. Moreover, quality of life is an important outcome in psychiatric patients. This study investigated the interaction between these features and its effect on mood disorder patient’s quality of life.Methods: Early-onset major depressive disorder (MDD), bipolar disorder I (BD I), and bipolar disorder II (BD II) patients were recruited. Excluding 18 patients who were missing data on main variables and 5 patients who were classified as severely ill, a total of 472 euthymic patients (MDD=167, BD I=133, BD II= 172) were assessed on their chronotype, trait impulsivity, and quality of life using self-reports.Results: Both impulsivity and eveningness were negatively associated with quality of life. Regression results showed that there was a significant interaction effect between eveningness and impulsivity on quality of life. This indicates that the higher the level of impulsivity in mood disorder patients, the negative effect of eveningness on quality of life increased.Conclusion: The current study suggests that examination of impulsive personality in relation to chronotype may be important in further understanding the effects of these features on mood disorder patients’ lives.

1 May 2026 in Crisis
Verified
Journal Article
Closed access
MCMinjae Choi
Minjae Choi
YYYeaseul Yoon
Yeaseul Yoon
YLYo Han Lee
Yo Han Lee
HHHyun-Hee Heo
Hyun-Hee Heo
MKMyung Ki
Myung Ki
Background: Suicidal ideation changes over time. Few studies have examined socioeconomic inequalities in suicide ideation regarding interrelated indicators of incidence, persistence, and remission. Aim: We aimed to investigate how socioeconomic characteristics are related to the incidence, persistence, and remission of suicidal ideation in South Korea. Methods: We assessed the incidence of suicidal ideation at the 1-year follow-up among individuals without prior suicidal ideation and its persistence and remission at the 2-year follow-up. We conducted a multinomial logistic regression analysis to examine the association between SES and three indicators of the course of suicidal ideation. Results: Among 8,334 respondents, the 12-month incidence of suicidal ideation was 2.1%. Among these cases, 18.5% persisted, while 81.5% remitted. Low SES, particularly income, was strongly associated with the incidence, persistence, and remission of suicidal ideation. The socioeconomic association was strongest for persistent suicidal ideation (adjusted odds ratio [aOR]: 3.66; 95% confidence interval [CI]: 1.47–9.10), followed by incidence (aOR: 1.59; 95% CI: 1.10–2.29) and remission (aOR: 1.32; 95% CI: 0.88–1.97) of suicidal ideation. Limitations: We could not examine changes in these risk factors during the follow-up period. Conclusion: Adverse socioeconomic circumstances may precipitate the worsening in the course of suicidal ideation. Addressing the socioeconomic determinants of suicidal ideation should be prioritized.